A team built for regulatory excellence
PhD scientists, a certified project manager, government mentors, and active cancer researchers united by one mission: helping your therapy reach patients faster.
Founder & CEO
Dr. Abhijit Chakraborty
Ph.D, PMP
The rare combination of scientific depth and execution
Abhijit founded CellGene Nexus to address a recurring gap in the Texas biotech ecosystem: early-stage oncology and cell/gene therapy programs that showcase breakthrough science but lack a clear path to FDA approval.
As a PhD scientist and certified Project Management Professional, Abhijit offers a unique blend of rigorous scientific judgment and disciplined execution. Every engagement is personally led by Abhijit — no junior hand-offs, no vague advice.
Rooted in the Houston/TMC ecosystem, the world's largest medical center, Abhijit connects clients to a network of trusted CROs, CDMOs, and translational partners while maintaining a reach that is scalable nationwide.
View LinkedIn profile
Chief Regulatory & Strategy Advisor · MedTech Mentor · VC Limited Partner
Dr. Dhriti Roy
Ph.D, MBA
Regulatory thought leader at the intersection of science, policy, and capital
Dr. Roy's influence spans government, academia, and venture capital — a rare profile that makes her uniquely valuable to early-stage healthcare founders navigating complex FDA approval and market access challenges.
As a U.S. Department of Commerce MedTech Mentor, she advises founders and investors on FDA readiness, regulatory risk, and scalable execution strategies. At Oxford, she serves as a life sciences platform leader bridging academic discovery and commercialization.
As a limited partner in select venture capital firms, Dr. Roy ensures that regulatory milestones are structured to de-risk programs for fundraising — not just for FDA approval.
View LinkedIn profile
Scientific Director · Drug Discovery · T-Cell · Immunotherapy
Dr. Faisal Aziz
Ph.D
Translational oncology scientist bridging molecular discovery and therapeutic innovation
Dr. Faisal Aziz is a Scientist at the Hormel Institute, University of Minnesota — one of the nation's leading cancer research centers. His work sits at the intersection of drug discovery, nucleotide metabolism, T-cell immunotherapy, and cancer biology.
His research focuses on the molecular mechanisms underlying gastric and inflammation-associated cancers, integrating structural biology, immunology, and translational disease models to uncover therapeutic pathways and novel disease biomarkers.
An accomplished scholar, Dr. Aziz has authored numerous peer-reviewed publications and actively contributes as a manuscript reviewer and editorial board member for several international biomedical journals.
View LinkedIn profileWhy our team is different
Expert guidance
Deep specialization in cell and gene therapy with a thorough understanding of the regulatory landscapes required for FDA approval.
Government and academic credibility
A U.S. Department of Commerce mentor and an Oxford platform leader on the team — institutional credibility that signals trust to investors and the FDA alike.
Investor-aligned regulatory strategy
Regulatory milestones structured to de-risk your program for fundraising, not just for FDA approval.
PMP project discipline
IND timelines managed with the rigor of a structured project — clear milestones, accountability, and no surprises.
Active research, not just consulting
Our team actively publishes in oncology and cancer biology, bringing preclinical strategy informed by ongoing bench and clinical work.
T-cell and immunotherapy depth
Expertise in T-cell immunotherapy, nucleotide metabolism, and biomarker discovery directly enhancing CAR-T and cell therapy IND packages.
Work directly with our leadership team
Every engagement is senior-led. No junior hand-offs, no vague advice.
Book a Discovery Call